Welcome to our dedicated page for FEMASYS news (Ticker: FEMY), a resource for investors and traders seeking the latest updates and insights on FEMASYS stock.
Femasys Inc. develops biomedical products for women’s reproductive health, with news centered on fertility treatment, fallopian tube assessment, and non-surgical permanent birth control. Its portfolio includes FemaSeed intratubal insemination, FemaSeed Complete for in-office fertility care, FemVue for ultrasound-based fallopian tube evaluation, FemBloc permanent birth control, and related diagnostic products such as FemChec.
Recurring updates cover product commercialization in OB/GYN settings, international distribution and market access, regulatory approvals outside the United States, U.S. clinical and regulatory development for FemBloc, reimbursement-related developments, financing, operating results, and governance changes.
Femasys (NASDAQ:FEMY) reported second-quarter and six-month 2026 results and a major financing. The company completed a $30 million private placement with potential proceeds up to $90 million upon full cash exercise of warrants, and subsequently believes it has resources to execute its U.S. commercial and clinical strategy.
For the six months ended June 30, 2026, sales were $756,716, up 0.8% year over year, with net loss $3.6 million versus $10.5 million in 2025, helped by a 25.7% reduction in R&D expenses. For Q2 2026, sales declined 18.9% to $331,827 and net loss was $4.5 million. Cash was $1.4 million at June 30, 2026, before the private placement.
Corporate updates include regaining Nasdaq listing compliance, new U.S. and international patents for FemBloc, CE Mark approval for FemHSG Catheter, initial commercial use and launch of FemaSeed Complete, a commercialization partnership in Israel, and appointment of a new COO.
Femasys (NASDAQ:FEMY) announced new issued patents in the United States and multiple key international markets that protect the blended polymer component of FemBloc, its non-surgical permanent birth control technology. These patents complement existing delivery system patents, broadening and extending FemBloc’s global intellectual property coverage.
The protected blended polymer is delivered into both fallopian tubes, degrades, and induces scar tissue for permanent occlusion. FemBloc is approved for marketing in Europe and select international markets but remains investigational in the United States, where a pivotal clinical trial is ongoing.
Femasys (NASDAQ:FEMY) entered a securities purchase agreement for a $30 million private placement with accredited investors led by Nantahala Capital, joined by Rosalind Advisors and company management. Closing is subject to customary conditions and is expected around August 10, 2026.
The company is selling an aggregate of 9,374,999 common shares and pre-funded warrants, plus accompanying warrants to purchase 18,749,998 common shares. The purchase price is $3.20 per share and $3.1999 per pre-funded warrant, with pre-funded warrants exercisable at $0.0001 per share. Accompanying warrants have a $2.95 exercise price and three-year term. If fully exercised for cash, warrants could provide up to an additional $60 million.
Milestone warrants for 9,374,999 shares become exercisable 12 months after closing and require specified U.S. revenue and share-price milestones plus an effective resale registration statement. According to Femasys, proceeds will support commercialization of its fertility portfolio and advancement of the U.S. FemBloc clinical and regulatory program.
Femasys (NASDAQ:FEMY) announced it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing. Nasdaq confirmed the matter is now closed.
According to Femasys, the company will now focus on advancing strategic priorities and expanding access to its reproductive health solutions.
Femasys (NASDAQ:FEMY) received CE Mark approval for its FemHSG Catheter, expanding its fertility care portfolio in Europe through commercial partners. Used with the FemVue device, FemHSG supports streamlined, in-office ultrasound-based evaluation during the initial fertility workup, enhancing OB/GYNs’ ability to provide comprehensive, accessible fertility diagnosis and care.
Femasys (NASDAQ: FEMY) reported results for the quarter ended March 31, 2026, highlighting early commercial adoption of FemaSeed Complete, initiation of the FINALE pivotal trial for FemBloc, new international distribution partnerships, and leadership additions.
Financials: Q1 sales $424,889 (+24.5% YoY), R&D -55.9% to $1.31M, net income of $846,100, cash ~$5.4M expected to fund operations into Q3 2026, accumulated deficit ~$145.0M.
Femasys (NASDAQ: FEMY) announced the first revenue-generating commercial use of its fertility portfolio in the OBGYN setting on May 5, 2026, deploying FemaSeed as a first-line infertility treatment with supporting FemSperm for in-office sperm preparation.
The company says this enables earlier, lower-cost, in-office fertility care within routine OB/GYN practice and follows earlier-than-expected U.S. FDA clearance and clinical validation of FemaSeed.
Femasys (NASDAQ: FEMY) announced the commercial launch of FemaSeed Complete on April 22, 2026, a fertility solution enabling OB/GYNs to perform first-line insemination entirely in-office.
The product targets expanded access: an estimated 10 million U.S. women with infertility, leverage of >b>40,000 OB/GYNs versus fewer than 2,000 infertility specialists, and will be showcased at ACOG May 1–3, 2026.
Femasys (NASDAQ: FEMY) announced a strategic partnership with AMI Technologies to commercialize its fertility portfolio in Israel on April 16, 2026. The collaboration will introduce FemaSeed as a first-line infertility treatment and deploy FemVue for ultrasound diagnosis of tubal factors, leveraging AMI’s local commercial infrastructure to accelerate physician adoption.
This move aims to expand international market access, increase physician awareness across key fertility centers, and support broader patient access to non-surgical fertility solutions.
Femasys (NASDAQ: FEMY) appointed John Canning as Chief Operating Officer effective April 1, 2026. Mr. Canning brings over 25 years of medical device operations and technology leadership to support commercialization of FemBloc and FemaSeed.
The company granted a 150,000-share inducement option, vesting 25% after one year and quarterly annual vesting thereafter, approved under Nasdaq Listing Rule 5635(c)(4).